A review of the health-related quality of life and economic impact of Parkinson's disease.
about
Herbal medicines for Parkinson's disease: a systematic review of randomized controlled trialsA randomized, placebo controlled pilot trial of botulinum toxin for paratonic rigidity in people with advanced cognitive impairmentProgression of voice and speech impairment in the course of Parkinson's disease: a longitudinal study.Cost effectiveness of preventing falls and improving mobility in people with Parkinson disease: protocol for an economic evaluation alongside a clinical trialDeterminants of generic and specific health-related quality of life in patients with Parkinson's diseaseAn Evaluation of the Proposed Worker Protection Standard with Respect to Pesticide Exposure and Parkinson's Disease.Health-related quality of life in Parkinson disease: correlation between Health Utilities Index III and Unified Parkinson's Disease Rating Scale (UPDRS) in U.S. male veteransHealth-related quality of life and strain in caregivers of Australians with Parkinson's disease: an observational studyEconomic evaluation of occupational therapy in Parkinson's disease: A randomized controlled trial.Measurement of patient-centered outcomes in Parkinson's disease: what do patients really want from their treatment?Do neurologists in Germany adhere to the national Parkinson's disease guideline?Lack of information and access to advanced treatment for Parkinson's disease patientsEffectiveness of occupational therapy in Parkinson's disease: study protocol for a randomized controlled trialDeath in the substantia nigra: a motor tragedy.National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on diseasePharmacotherapy for Parkinson's disease.Patient and caregiver quality of life in Huntington's diseaseNovel investigational adenosine A2A receptor antagonists for Parkinson's disease.Loss of ability to work and ability to live independently in Parkinson's disease.The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal.Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson's disease.The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis.Estimating the direct and indirect costs associated with Parkinson's disease.Mitochondrial optic neuropathy: In vivo model of neurodegeneration and neuroprotective strategies.The effects of vasoactive intestinal peptide in neurodegenerative disorders.Discordance Between Physician Assessment and Patient-Reported Depressive Symptoms in Parkinson Disease.The Profile of Long-term Parkinson's Disease Survivors with 20 Years of Disease Duration and Beyond.Successful use of rasagiline in combination with two antidepressants: a case report.The health-related, social, and economic consequences of parkinsonism: a controlled national study.Move for Change Part III: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's Disease.The current and projected economic burden of Parkinson's disease in the United States.Average annual cost of Parkinson's disease in São Paulo, Brazil, with a focus on disease-related motor symptoms.The analysis of relationship between selected sociodemografic factors and disorders of speech organs in Parkinson`s patients.Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.Experiences of caregivers of people with Parkinson's disease in Singapore: a qualitative analysis.Evaluation of the Parkinson's KinetiGraph in monitoring and managing Parkinson's disease.Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.Quality of life and burden in caregivers for patients with Parkinson's disease: concepts, assessment and related factors.Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.
P2860
Q27012917-C1FDB6F1-54D6-4E60-855A-3AB0029D09D0Q28542828-8D6B2478-C042-41EF-8D3E-734A860A6C50Q30444925-E711EAB4-700C-4271-AE9F-DE81B958AC46Q33372608-8B55208C-669C-454A-91A7-C4431C010050Q33834634-2B8B51A6-BDFE-422E-BD1E-F2EC96411B01Q33839894-431A3907-E248-481D-A7C7-2CECC34FB32BQ34128695-3E4B3F8B-3A52-4473-B18C-F2F0B5432DCBQ34340178-FBE1D799-759F-40FA-AD69-956366704A0EQ34470840-E97B0E63-2F6D-445C-8252-A538EA864E0FQ34556713-32E53A47-A70F-4300-8F3B-6BE06F251ADBQ34879044-F8065DD7-B542-48C8-9D22-FD3EE49E1F25Q35666376-63FE890F-146D-4509-A6A9-3EBA64FA0890Q36689403-1E531703-0A68-4AD0-91D9-8898A93EE439Q36847262-FB3F0400-6DD4-4FA8-A5A7-9886536B25A3Q36992154-0DE661A0-2B41-413D-A50C-1A4286558EF7Q37016031-3B9CF099-DBF0-4C7F-BF0F-52755E10BE9EQ37212835-4A1DCFDB-9631-4207-AE2E-1D14B3BC7D93Q37627259-88789873-C141-48D9-BC0E-8440FB441E6BQ37687797-4AE771DA-A0A5-4E38-8FD4-AFB18B6358A5Q37891050-37CC4434-0D9E-4CAD-989E-CD46884911F0Q38046734-E424966F-E455-4622-A633-53A1DB9A34ABQ38140733-0B2C9283-E2BF-48A5-B0F2-54FE49122597Q38618871-FE6F5261-80AF-418B-95F2-C0EC18980874Q38766331-76545CDB-B61F-4A71-83BC-22E9FAF7EB9AQ38992271-C675ED23-7AFF-481E-83CF-7AB04D90C092Q40189130-4565829B-91B7-42D6-AF46-385C927081C2Q41346651-D75D2641-51DC-4A7A-BD3C-2724BD356A77Q42932271-4BBF2534-207B-4455-B500-50CD53303191Q43608397-F471742E-A3AB-44C9-8FFB-D8923DA83863Q44071700-7D79EDAA-7E69-4094-A1EA-C72FD409503FQ44988421-48461286-18B8-4D27-9F42-0DC6FDF99F96Q47098412-7E85BD90-75DE-43BA-9B92-CB5C8DEB6FE9Q47100606-E530F84D-6F82-437A-B64C-97BAFD268952Q47215658-DA7A388E-CDFB-4BFE-B373-856A630B68E6Q47392450-095447DD-F972-4812-9EF0-E912D71FF9A4Q47557053-803771A9-E187-4EC8-A585-5C6F0A751347Q48093163-2A809183-F623-4A7F-94A1-3313A50F6A0AQ48289765-90003C41-37EE-4896-ADC4-4F6A528C219EQ48461424-71DC1098-186B-4D86-B6AF-D062A736B164Q48583756-810563F4-25DC-4034-B91E-057C6CC8B4FF
P2860
A review of the health-related quality of life and economic impact of Parkinson's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A review of the health-related ...... impact of Parkinson's disease.
@ast
A review of the health-related ...... impact of Parkinson's disease.
@en
type
label
A review of the health-related ...... impact of Parkinson's disease.
@ast
A review of the health-related ...... impact of Parkinson's disease.
@en
prefLabel
A review of the health-related ...... impact of Parkinson's disease.
@ast
A review of the health-related ...... impact of Parkinson's disease.
@en
P2093
P2860
P1433
P1476
A review of the health-related ...... impact of Parkinson's disease.
@en
P2093
Claire L Shenton
Clare H Dowding
Sam S Salek
P2860
P304
P356
10.2165/00002512-200623090-00001
P577
2006-01-01T00:00:00Z
P6179
1018082711